# A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

> **NCT07098338** · PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 278 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Rilvegostomig
- **DRUG:** Ramucirumab
- **DRUG:** Dato-DXd

## Key facts

- **NCT ID:** NCT07098338
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-07
- **Primary completion:** 2029-04-06
- **Final completion:** 2029-04-06
- **Target enrollment:** 278 (ESTIMATED)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07098338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07098338, "A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07098338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*